Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356291 | 0.78 | CHRNA7 (0.36) | SCDCHRNA7HTR3AKCNH2 | |
| SCHEMBL5353576 | 0.74 | SCD (0.43) | SCDCHRNA7HTR3AKMT2A | |
| SCHEMBL5351784 | 0.74 | IL4I1 (0.44) | SCDCHRNA7NPC1RAB9AKLF5 | |
| SCHEMBL5352859 | 0.74 | CHRNA7 (0.36) | SCDCHRNA7HTR3AKCNH2 | |
| SCHEMBL7512345 | 0.74 | CHRNA7 (0.52) | SCDCHRNA7HTR3A | |
| SCHEMBL2637923 | 0.74 | HRH3 (0.36) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL5351339 | 0.73 | SCD (0.38) | SCDCHRNA7HTR3AKCNH2 | |
| SCHEMBL5347172 | 0.73 | CHRNA7 (0.36) | SCDCHRNA7HTR3AKCNH2 | |
| SCHEMBL2638898 | 0.72 | CHRNA7 (0.60) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL3202084 | 0.70 | CYP1A2 (0.46) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223753-B2 | Diazabicyclic biaryl derivatives | NEUROSEARCH A/S (DK) | 2007-05-29 | — | — | US | claimed |
| EP-1562945-B1 | 1,4-DIAZABICYCLO(3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH AS (DK) | 2006-11-15 | — | — | EP | claimed |
| EP-1562945-A1 | 1,4-DIAZABICYCLO(3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH A/S (DK) | 2005-08-17 | — | — | EP | claimed |
| US-20040127491-A1 | Novel diazabicyclic biaryl derivatives | ANIONA APS (DK) | 2004-07-01 | — | — | US | claimed |
| WO-2004043960-A1 | 1,4-DIAZABICYCLO (3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH A/S (DK) | 2004-05-27 | — | — | WO | claimed |
| US-7223753-B2 | Diazabicyclic biaryl derivatives | NEUROSEARCH A/S (DK) | 2007-05-29 | — | — | US | disclosed |
| EP-1562945-B1 | 1,4-DIAZABICYCLO(3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH AS (DK) | 2006-11-15 | — | — | EP | disclosed |
| EP-1562945-A1 | 1,4-DIAZABICYCLO(3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH A/S (DK) | 2005-08-17 | — | — | EP | disclosed |
| US-20040127491-A1 | Novel diazabicyclic biaryl derivatives | ANIONA APS (DK) | 2004-07-01 | — | — | US | disclosed |
| WO-2004043960-A1 | 1,4-DIAZABICYCLO (3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH A/S (DK) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127491-A1 | Novel diazabicyclic biaryl derivatives | CHRNA6, CHRNA3, CHRNA2 | SCD 968/4885CHRNA7 5/4885NPC1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.